Evidence map›Paper›PMID 39263278›Full record

ArticleJCEM case reports2024

Hematologic Malignancies: Two Cases of a Rare Cause of Hypopituitarism.

Brian Lauzon, Tala Abu-Hijleh, Natalia McInnes, Ally Prebtani

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Brian LauzonDepartment of Medicine, Division of Endocrinology & Metabolism, McMaster University, Hamilton L8S 4L8, Ontario, Canada.ORCID https://orcid.org/0000-0002-3883-3724
Tala Abu-HijlehDepartment of Medicine, Division of Endocrinology & Metabolism, McMaster University, Hamilton L8S 4L8, Ontario, Canada.
Natalia McInnesDepartment of Medicine, Division of Endocrinology & Metabolism, McMaster University, Hamilton L8S 4L8, Ontario, Canada.ORCID https://orcid.org/0000-0003-1495-3825
Ally PrebtaniDepartment of Medicine, Division of Endocrinology & Metabolism, McMaster University, Hamilton L8S 4L8, Ontario, Canada.ORCID https://orcid.org/0000-0001-6767-7313

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematologic malignancies are rare causes of sellar masses and hypopituitarism. We report 2 cases of hypopituitarism due to sellar masses from hematologic malignancies. The first patient was found to have hypopituitarism but initial non-gadolinium-enhanced magnetic resonance imaging (MRI) sella did not demonstrate a mass. Subsequent gadolinium-enhanced MRI and transsphenoidal biopsy confirmed a diagnosis of intravascular lymphoma. Treatment with systemic chemotherapy resulted in resolution of abnormalities on MRI. The second patient had a known diagnosis of chronic lymphocytic leukemia, and sellar involvement contributing to hypopituitarism was confirmed on biopsy. Treatment with ibrutinib, acalabrutinib, and stereotactic radiosurgery resulted in resolution of abnormalities on MRI. Both patients were treated with hormone replacement for hypopituitarism. These cases highlight that hematologic malignancies should be suspected as causes of sellar masses/hypopituitarism in patients with concurrent symptoms atypical for a pituitary adenoma (eg, constitutional symptoms), known diagnoses of hematologic malignancies, or rapid tumor growth and invasion on imaging. Gadolinium-enhanced MRI should be pursued if nonenhanced MRI is nondiagnostic. Transsphenoidal biopsy can be considered for diagnosis. Malignancy-directed systemic therapy may improve hypopituitarism and radiographic abnormalities on MRI.

Indexed as

hypopituitarismleukemialymphomasellar mass

Identifiers

PMID39263278
PMCPMC11387999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.